Form 4: Bone Biologics Director Bruce Stroever Receives New Stock Option Grant

Bone Biologics Corp. Director Bruce Stroever was granted 62,894 non-employee stock options with an exercise price of $0.88, vesting quarterly over one year.

Summary

• Bruce Stroever, a Director at Bone Biologics Corp. (BBLG), reported a new grant of 62,894 non-employee stock options on June 4, 2025.
• The newly granted options have an exercise price of $0.88 per share and an expiration date of June 4, 2035.
• These options were granted under the Bone Biologics Corporation 2015 Equity Incentive Plan and will vest in four equal quarterly installments.
• In addition to the new grant, Mr. Stroever beneficially owns other non-employee stock options with various exercise prices and vesting statuses, including 30,713 options at $1.73, 10,721 options at $5.12, 154 options at $387.28, 37 options at $844.8, and 13 options at $1,260.
• The options granted on September 17, 2024 (30,713 shares) also vest in four equal quarterly installments, while the remaining older options are fully exercisable as of the report date.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates a routine compensation event that aligns director interests with shareholders. There are no negative operational or financial disclosures, though the high exercise prices of older options could be a minor concern if the stock price is significantly lower.

Positives

• The grant of new stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The exercise price of $0.88 for the new options is relatively low, suggesting potential for future value if the stock price appreciates.

Negatives

• The exercise of these options in the future could lead to a degree of share dilution for existing shareholders.
• Several older stock options held by the director have significantly higher exercise prices ($5.12, $387.28, $844.8, $1,260), which may indicate that the company's stock price has traded below these levels, potentially limiting their current intrinsic value.

Future Outlook

The new stock options will vest in four equal quarterly installments, indicating a future increase in the director's exercisable equity holdings over the next year. The expiration dates of various options extend up to 2035, providing a long-term incentive horizon.

Industry Context

This Form 4 filing is a routine disclosure of insider compensation, common across all publicly traded companies. It reflects standard corporate governance practices where directors receive equity-based incentives to align their interests with long-term shareholder value. The specific details relate to Bone Biologics Corp., a company likely in the biotechnology or medical device sector, where such equity compensation is a typical component of executive and director remuneration.

Corporate Governance

Related Party Transactions

• The grant of non-employee stock options to Bruce Stroever, a Director of Bone Biologics Corp., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also benefit from increased alignment of director's interests with long-term stock performance.
• Employees (specifically the director): Direct financial incentive tied to the company's stock performance.

Next Steps

• The newly granted 62,894 options will vest in four equal quarterly installments following the grant date of June 4, 2025.
• The director may choose to exercise vested options at their respective exercise prices before their expiration dates.

Key Dates

Keywords

Bone Biologics Corp, BBLG, SEC Form 4, Stock Options, Director Compensation, Equity Incentive Plan, Insider Transaction, Beneficial Ownership